Drawing for Serial No. 79205785

USPTO serial 79205785

Serial No. 79205785

Reviewed by CopyMark Law Group

Reg. 5308919Status 709
Filing date
Status date
Registration date
Oct 17, 2017
Examiner
STRUCK, ROBERT J
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79205785?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 4, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Mar 18, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Mar 18, 2025INPCINVALIDATION PROCESSED—
Jan 4, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 3, 2024C71TCANCELLED SECTION 71—
Oct 17, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 16, 2018FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 29, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 29, 2018FIMPFINAL DISPOSITION PROCESSED—
Jan 17, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 17, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 1, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 1, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 12, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 22, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 20, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 3, 2017RFNTREFUSAL PROCESSED BY IB—
May 23, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 23, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 12, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 12, 2017RFRRREFUSAL PROCESSED BY MPU—
May 6, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 5, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 2, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 28, 2017DOCKASSIGNED TO EXAMINER—
Apr 28, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 21, 2017LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Apr 20, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance